DK3615534T3 - Kondenserede pentacykliske imidazolderivater som modulatorer af TNF-aktivitet - Google Patents

Kondenserede pentacykliske imidazolderivater som modulatorer af TNF-aktivitet Download PDF

Info

Publication number
DK3615534T3
DK3615534T3 DK18719178.8T DK18719178T DK3615534T3 DK 3615534 T3 DK3615534 T3 DK 3615534T3 DK 18719178 T DK18719178 T DK 18719178T DK 3615534 T3 DK3615534 T3 DK 3615534T3
Authority
DK
Denmark
Prior art keywords
modulators
imidazole derivatives
tnf activity
condensed pentacyclic
pentacyclic imidazole
Prior art date
Application number
DK18719178.8T
Other languages
English (en)
Inventor
Daniel Christopher Brookings
Haro Garcia Teresa De
Yann Foricher
Helen Tracey Horsley
Martin Clive Hutchings
James Andrew Johnson
Coss Malcolm Mac
Mengyang Xuan
Zhaoning Zhu
Original Assignee
Sanofi Sa
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3615534(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, UCB Biopharma SRL filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK3615534T3 publication Critical patent/DK3615534T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18719178.8T 2017-04-25 2018-04-24 Kondenserede pentacykliske imidazolderivater som modulatorer af TNF-aktivitet DK3615534T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25
PCT/EP2018/060489 WO2018197503A1 (en) 2017-04-25 2018-04-24 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (1)

Publication Number Publication Date
DK3615534T3 true DK3615534T3 (da) 2021-10-18

Family

ID=58632834

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18719178.8T DK3615534T3 (da) 2017-04-25 2018-04-24 Kondenserede pentacykliske imidazolderivater som modulatorer af TNF-aktivitet

Country Status (33)

Country Link
US (4) US10980814B2 (da)
EP (2) EP3615534B1 (da)
JP (2) JP7083358B2 (da)
KR (1) KR102565132B1 (da)
CN (1) CN110582495B (da)
AR (1) AR111426A1 (da)
AU (1) AU2018259040B2 (da)
CA (1) CA3058980A1 (da)
CL (1) CL2019002875A1 (da)
CO (1) CO2019012856A2 (da)
CR (1) CR20190526A (da)
DK (1) DK3615534T3 (da)
EA (1) EA039049B1 (da)
ES (2) ES2893807T3 (da)
HR (1) HRP20211927T1 (da)
HU (1) HUE056593T2 (da)
IL (1) IL269890B (da)
LT (1) LT3615534T (da)
MA (2) MA49055B1 (da)
MX (1) MX2019012443A (da)
MY (1) MY197212A (da)
PE (1) PE20200662A1 (da)
PH (1) PH12019502182B1 (da)
PL (2) PL3939980T3 (da)
PT (2) PT3939980T (da)
PY (1) PY1829804A (da)
RS (1) RS62596B1 (da)
SG (1) SG11201908871SA (da)
SI (1) SI3615534T1 (da)
TW (1) TWI801378B (da)
UY (1) UY37700A (da)
WO (1) WO2018197503A1 (da)
ZA (1) ZA201906255B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766906B2 (en) * 2016-04-01 2020-09-08 UCB Biopharma SRL Fused hexacyclic imidazole derivatives as modulators of TNF activity
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3117344A1 (en) * 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
CN120418259A (zh) 2022-11-23 2025-08-01 弗沃德医疗公司 TNFα活性的调节剂
TW202508596A (zh) 2023-04-26 2025-03-01 法商賽諾菲公司 使用腫瘤壞死因子α之小分子抑制劑治療乾癬
WO2024251282A1 (zh) * 2023-06-09 2024-12-12 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
TW202519231A (zh) 2023-07-04 2025-05-16 法商賽諾菲公司 結晶形式
TW202521544A (zh) 2023-08-16 2025-06-01 美商雷瑟拉股份有限公司 TNFα活性調節劑及其用途
WO2025068505A1 (en) 2023-09-29 2025-04-03 Sanofi Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation
TW202602881A (zh) * 2024-03-27 2026-01-16 大陸商海思科醫藥集團股份有限公司 雜環衍生物及其在醫藥上的應用
WO2025212627A1 (en) 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用
WO2025252251A1 (zh) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 含氧杂环类衍生物抑制剂、其制备方法和应用
WO2026012303A1 (en) * 2024-07-09 2026-01-15 Hangzhou Highlightll Pharmaceutical Co., Ltd NOVEL BENZO [4, 5] IMIDAZO COMPOUNDS AS TNFα MODULATORS
WO2026022134A1 (en) 2024-07-23 2026-01-29 Sanofi Novel aminocarbonylation processes
WO2026021586A1 (zh) * 2024-07-26 2026-01-29 上海瀚辰星泰医药科技有限公司 一种多环化合物及其制备方法和应用
WO2026027449A1 (en) 2024-07-29 2026-02-05 Sanofi Fused pentacyclic imidazole derivatives
WO2026051930A1 (zh) * 2024-09-04 2026-03-12 苏州湃玥生物科技有限公司 一种作为tnf活性调节剂的稠合五环苯并咪唑衍生物及其制备方法和应用
WO2026055519A1 (en) 2024-09-06 2026-03-12 Rapt Therapeutics, Inc. Fused ring imidazole compounds
WO2026064602A1 (en) * 2024-09-23 2026-03-26 Synnovation Therapeutics, Inc. HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFα ACTIVITY
WO2026068677A1 (en) 2024-09-27 2026-04-02 Sanofi Processes for the preparation of fused pentacyclic imidazoles and intermediates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550737B2 (en) * 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
CN104619709B (zh) * 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MX380578B (es) * 2014-10-03 2025-03-12 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados.
EP3288939A1 (en) * 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling

Also Published As

Publication number Publication date
HRP20211927T1 (hr) 2022-03-18
US20210252012A1 (en) 2021-08-19
AU2018259040A1 (en) 2019-10-31
MA49055A (fr) 2021-05-05
MA57699B1 (fr) 2023-11-30
PH12019502182B1 (en) 2024-01-31
CR20190526A (es) 2020-01-07
UY37700A (es) 2018-11-30
JP7299382B2 (ja) 2023-06-27
CL2019002875A1 (es) 2020-03-06
EP3939980B1 (en) 2023-07-26
US20200046723A1 (en) 2020-02-13
KR102565132B1 (ko) 2023-08-08
SI3615534T1 (sl) 2022-01-31
AR111426A1 (es) 2019-07-10
AU2018259040B2 (en) 2022-04-28
EP3615534B1 (en) 2021-09-15
CN110582495A (zh) 2019-12-17
JP2022116233A (ja) 2022-08-09
PL3615534T3 (pl) 2022-01-31
LT3615534T (lt) 2021-11-25
TWI801378B (zh) 2023-05-11
SG11201908871SA (en) 2019-10-30
PY1829804A (es) 2019-03-01
IL269890B (en) 2022-03-01
WO2018197503A1 (en) 2018-11-01
ZA201906255B (en) 2021-01-27
ES2956555T3 (es) 2023-12-22
HUE056593T2 (hu) 2022-02-28
MA49055B1 (fr) 2021-12-31
BR112019020314A2 (pt) 2020-04-28
EA201992407A1 (ru) 2020-04-06
MX2019012443A (es) 2020-01-13
EA039049B1 (ru) 2021-11-26
KR20190141200A (ko) 2019-12-23
US20230250105A1 (en) 2023-08-10
RS62596B1 (sr) 2021-12-31
JP7083358B2 (ja) 2022-06-10
PE20200662A1 (es) 2020-06-11
EP3615534A1 (en) 2020-03-04
ES2893807T3 (es) 2022-02-10
PT3615534T (pt) 2021-10-21
US10980814B2 (en) 2021-04-20
PH12019502182A1 (en) 2020-06-08
JP2020517637A (ja) 2020-06-18
CO2019012856A2 (es) 2020-01-17
EP3939980A1 (en) 2022-01-19
PL3939980T3 (pl) 2024-02-05
TW201841918A (zh) 2018-12-01
US20250127795A1 (en) 2025-04-24
NZ758198A (en) 2024-01-26
CN110582495B (zh) 2022-04-01
PT3939980T (pt) 2023-08-07
CA3058980A1 (en) 2018-11-01
MY197212A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
DK3615534T3 (da) Kondenserede pentacykliske imidazolderivater som modulatorer af TNF-aktivitet
DK3625228T3 (da) Pyrimidinderivater som pge2-receptormodulatorer
DK3321265T3 (da) 4,6-diamino-pyrido[3,2-d]pyrimidinforbindelser og deres udnyttelse som modulatorer af toll-lignende receptorer
DK3394033T3 (da) Heterocykliske forbindelser som immunmodulatorer
EP3383386A4 (en) MODULATORS OF CHEMOKIN RECEPTORS
DK3668851T3 (da) Fremgangsmåde til fremstilling af thiocarbonater
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
LT3322701T (lt) Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3331876T3 (da) Modulators of ror-gamma
DK3294720T3 (da) Fremgangsmåde til fremstilling af terpinolenepoxid
DK3197868T3 (da) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrol-negative allosteriske modulatorer af nr2b
DK3178817T3 (da) Amorf form af tetracyklisk forbindelse
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
LT3377483T (lt) N-pakeistieji indolo dariniai kaip pge2 receptoriaus moduliatoriai
DK3204378T3 (da) N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
EP3654987A4 (en) USE OF AMINOALKYLBENZOTHIACEPINE DERIVATIVES
DK3105757T3 (da) Harmonisk båndbreddeudvidelse af audiosignaler
DK3536324T3 (da) 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139
DK3331863T3 (da) Hidtil ukendte forbindelser som ror-gamma-modulatorer
DK2964229T3 (da) Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren
DK3389692T3 (da) Modulatorer af komplement-aktivitet
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin